A carregar...
Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy
Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibitor imatinib has become standard therapy for chronic myelogenous leukemia (CML), with most patients reaching total and durable remission. However, a significant fraction of patients develop resistance,...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497988/ https://ncbi.nlm.nih.gov/pubmed/28678800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0179700 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|